Skip to Content

Bristol-Myers Squibb Company BMY

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Bristol Posts Soft Q1 as COVID-19 Headwinds Weigh on Results, but Pipeline Potential Looks Strong

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Bristol reported first-quarter results slightly below our expectations partly due to COVID-19 headwinds, but we don’t expect any major changes to our fair value estimate based on the minor underperformance. We view the company as moderately undervalued with the market underappreciating one of the best developing late-stage pipelines, which also reinforces our wide moat rating.

Read Full Analysis

Company Profile

Business Description

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Contact
430 E. 29th Street, 14th Floor
New York, NY, 10016
T +1 212 546-4000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type High Yield
Employees 30,250

Related